Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Jiff (Palo Alto, CA) a commercial-stage health IT company focused on a HIPAA-compliant private healthcare social network and digital health application platform, closed a $7.5M Series A financing. Participants include Aeris Capital and Aberdare Ventures.

ImaginAb (Inglewood, CA) a clinical-stage biopharmaceutical company focused on re-engineered therapeutic antibody fragments against biologic targets for diagnostic imaging with Positron Emission Tomography scans for management of cancer and autoimmune disease, closed a $12.5M Series B financing. Participants include Novartis Venture Funds, Merieux Developpement, Nextech Invest, Cycad Group and Momentum Biosciences.

Genalyte (San Diego, CA) a clinical-stage medical device company focused on next-generation multiplexing technology, hardware and software for antibody, protein and nucleic acid assays for autoimmune diseases and other diseases, closed a $11.8M Series A financing. Participants include Redmile Group and Claremont Creek Ventures.

Phosphate Therapeutics (London, United Kingdom) a clinical-stage biopharmaceutical company focused on small molecules phosphate binders for hyperphosphatemia and renal failure, closed a $13.8M Series A financing. Participants include Inventages Venture Capital.

CN Creative (United Kingdom) a development-stage medical device company focused on electronic nicotine delivery devices and other nicotine replacement therapies for nicotine addiction and smoking cessation, closed a $3.1M Series A financing. Participants include Advent Life Sciences.

ImmuneXcite (Watertown, MA) a development-stage biopharmaceutical company focused on a therapeutic platform for the development of monoclonal antibodies and vaccines for cancer and infectious diseases, closed a $2.4M Series A financing. Participants include Boston Harbor Angels.

Heat Biologics (Chapel Hill, NC) a clinical-stage biopharmaceutical company focused on vaccines and antibodies for non-small cell lung cancer and stimulation of regulatory T cells, closed a $2.8M Series A financing. Participants include Brightline Ventures.

CrystalGenomics (Korea) a clinical-stage biopharmaceutical company focused on chemoproteomics based drug discovery company working on an NSAID, antibiotics for MRSA and HIF inhibitors for hypoxia, therapeutics for cancer, closed a third tranche of $2.6M Series A financing bringing the total round to $20M. Participants include Korea Seoul Life Sciences Fund, Hanwha Venture Capital and Oxford […]

MC10 (Cambridge, MA) a development-stage medical device company focused on flexible, portable electronic medical devices for diagnosing, monitoring body functions and performance via parameters such as the heart (ECG), brain (EEG), muscle (EMG), body temp and hydration, closed a $2M Series B financing, bringing the total round to $17.1M. Participants include Aberdare Ventures.

CN Creative (United Kingdom) a development-stage medical device company focused on electronic nicotine delivery devices and other nicotine replacement therapies for nicotine addiction and smoking cessation, closed a $1M Series A financing. Participants include Advent Life Sciences.

ImmuneXcite (Watertown, MA) a development-stage biopharmaceutical company focused on a therapeutic platform for the development of monoclonal antibodies and vaccines for cancer and infectious diseases, closed a $2.4M Series A financing. Participants include Boston Harbor Angels.

Warp Drive Bio (Cambridge, MA) a development-stage biopharma company focused on a proprietary genomic search engine to identify and develop natural product drug candidates in microbes to target previously undruggable targests, closed a $75M Series A financing. Participants include Third Rock Ventures, Greylock Partners and Sanofi.

BerGenBio (Norway) a preclinical-stage biopharma company focused on receptor tyrosine kinase inhibition for the treatment of cancer, closed a $8.8M Series A financing. Participants include Sarsia Seed and Investinor.

« Previous Page« Previous Entries  Next Entries »Next Page »

to top of page...